Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 4
1(50.0%)
2Total
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01793519Phase 4Active Not Recruiting

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Role: collaborator

NCT03411850Phase 2Unknown

Sjogrens Syndrome Measured by Ultrasound

Role: lead

NCT02471261Completed

Elastography as Gouty Arthropathy Outcome (EGO)

Role: lead

All 3 trials loaded